利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

510 条记录 (耗时 0.03 秒)

    TEGAFUR-CONTAINING COMPOSITION FOR SINGLE DAILY AND ALTERNATE-DAY DOSING
    136.
    发明公开
    TEGAFUR-CONTAINING COMPOSITION FOR SINGLE DAILY AND ALTERNATE-DAY DOSING 审中-公开
    TEGAFURHALTIGE ZUSAMMENSETZUNG ZUR EINMALIGEN ODER MEHRMALIGENTÄGLICHENDOSIERUNG

    公开(公告)号：EP2671590A1

    公开(公告)日：2013-12-11

    申请号：EP12741901.8

    申请日：2012-01-30

    申请人： Taiho Pharmaceutical Co., Ltd.

    发明人： YAMAUE, Hiroki ,  YAMAMITSU, Susumu ,  SHIRASAKA, Tetsuhiko

    IPC分类号： A61K31/513 ,  A61K31/4412 ,  A61K31/53 ,  A61P35/00 ,  A61P43/00

    CPC分类号： A61K31/513 ,  A61K31/4412 ,  A61K31/53 ,  A61K2300/00

    摘要： This invention provides an antitumor agent comprising a combination drug containing tegafur, gimeracil, and oteracil potassium, characterized by being repeatedly administered to a patient once a day every other day, four days a week, at a dose such that the tegafur is administered in an amount of 80 mg or more/dose when the patient has a body surface area of less than 1.25 m 2 , in an amount of 100 mg or more/dose when the patient has a body surface area of 1.25 to 1.5 m 2 , or in an amount of 120 mg or more/dose when the patient has a body surface area of not less than 1.5 m 2 .

    摘要翻译： 本发明提供了一种抗肿瘤剂，其包含含有替加氟，吉美脯氨酸和奥特拉西钾的组合药物，其特征在于每隔一天，每周四天一天一次地向患者重复施用，剂量使得替加氟以 当患者体表面积小于1.25m 2时，当患者体表面积为1.25至1.5m 2时，其量为100mg或更多/剂量，或者在 当患者的体表面积不小于1.5m 2时，其量为120mg以上/剂量。

    THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE
    138.
    发明授权
    THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE 有权
    治疗剂AGAINST炎症性肠病

    公开(公告)号：EP2005962B1

    公开(公告)日：2012-04-25

    申请号：EP07737060.9

    申请日：2007-04-12

    申请人： Taiho Pharmaceutical Co., Ltd.

    发明人： TAKEBAYASHI, Yuji

    IPC分类号： A61K31/506 ,  A61P1/04 ,  C07D403/06

    CPC分类号： C07D403/06 ,  A61K31/506

    摘要： Disclosed is a therapeutic agent for inflammatory bowel disease comprising 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl- 2,4(1H,3H)-pyrimidinedione or a pharmaceutically acceptable salt thereof as an active ingredient. An effective and safe therapeutic agent for inflammatory bowel disease including ulcerative colitis and Crohn's disease can be provided. The balance between the therapeutic effect on a chronic inflammation such as inflammatory bowel disease and the adverse side effect of the compound is superior to those of an aminosalicylic acid preparation and a corticosteroid preparation. The compound shows an unexpected effect beyond a mere antidiarrheal effect.